Overview A research team from Bose Institute , Kolkata, has challenged the long‑standing ‘universal σ‑cycle’ model of bacterial transcription. Their findings on M. tuberculosis could open novel avenues for anti‑TB drug design. Key Developments Contrary to the textbook model, not all σ factors dissociate from RNA polymerase during elongation. Three σ factors were examined: σA (housekeeping), σE (stress‑responsive) and σF (stress‑survival). σA and σE are released, while σF stays bound throughout transcription. The study, published in Nucleic Acids Research , employed in‑vitro transcription assays, fluorescence measurements, high‑resolution protein interaction analyses and chromatin immunoprecipitation (ChIP) for in‑vivo confirmation. Persistent σF‑RNA polymerase association suggests a dedicated mechanism to maintain expression of stress‑response genes, crucial for bacterial survival under hostile host conditions. Important Facts The research highlights that bacterial transcription regulation is more heterogeneous than previously thought. By demonstrating that σ‑factor architecture dictates interaction dynamics, the study identifies protein‑protein interfaces as potential drug targets, shifting focus from traditional enzyme‑active‑site inhibition, which often leads to resistance. UPSC Relevance Understanding the molecular basis of TB pathogenesis aligns with GS3 topics on emerging infectious diseases, antimicrobial resistance, and biotechnology‑driven solutions. The role of research institutions like the DST and autonomous bodies underscores the importance of scientific infrastructure in national health security. Way Forward Encourage interdisciplinary projects that integrate structural biology, microbiology and drug design to exploit σ‑factor–RNA polymerase interfaces. Strengthen funding for basic research on pathogen biology, as breakthroughs can translate into next‑generation antimicrobials. Incorporate recent molecular findings into medical curricula and UPSC preparatory material to reflect evolving scientific knowledge. Such strategic focus can aid India’s fight against drug‑resistant TB and enhance preparedness for future bacterial threats.